Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting

Prostate

Volumn 74, Issue 3, 2014, Pages 314-320

  Pienta, Kenneth J ^a   Walia, Guneet ^b   Simons, Jonathan W ^b   Soule, Howard R ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Prostate Cancer Foundation   (United States)

Author keywords

diagnostics; metastases; therapeutics; treatment resistance; tumor microenvironment

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; IPILIMUMAB; MITOXANTRONE; RADIUM; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; CACHEXIA; CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DRUG TARGETING; GENOTYPE; HUMAN; IMMUNOTHERAPY; METASTASIS; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; STEM CELL; TUMOR MICROENVIRONMENT;

EID: 84892445322     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22753     Document Type: Article

References (68)

1. Soloway MS, deKernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, Prout GR Jr, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP,. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 1981; 125 (5): 664-667.
2. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC,. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14 (6): 1756-1764.
3. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94 (19): 1458-1468.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-422.
6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154.
7. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C,. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361 (8): 745-755.
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
10. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213-223.
11. Nelson PS,. Molecular states underlying androgen receptor activation: A framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012; 30: 644-646.
12. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC,. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227 (3): 286-297.
13. Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades N,. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci USA 2013; 110 (17): 6997-7002.
14. Rodrigues DN, Butler LM, Estelles DL, de Bono JS,. Molecular pathology and prostate cancer therapeutics: From biology to bedside. J Pathol 2013; DOI: 10.1002/path.4272
15. Current concepts and approaches to the study of prostate cancer. Proceedings of a meeting. Prouts Neck, Maine, October 18-20, 1985. Prog Clin Biol Res 1987; 239: 1-820.
16. Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH,. Eleventh Prouts Neck Meeting on Prostate Cancer: Emerging strategies in prostate cancer therapy. Cancer Res 2007; 67 (20): 9613-9615.
17. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ,. The lethal phenotype of cancer: The molecular basis of death due to malignancy. CA Cancer J Clin 2007; 57 (4): 225-241.
18. Chou E, Simons JW,. The molecular biology of prostate cancer morbidity and mortality: Accelerated death from ejaculate poisoning ? Urol Oncol 1997 3 (3): 79-84.
19. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW,. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 1995; 45 (3) 542-549.
20. Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, Olmez F,. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori 2013; 99 (2): 229-233.
21. Pienta KJ, Robertson B, Coffey D, Taichman RS,. The Cancer Diaspora: Metastasis beyond the seed and soil hypothesis. Clin Cancer Res 2013; 19 (21): 5849-5855.
22. Camacho DF, Pienta KJ,. Disrupting the networks of cancer. Clin Cancer Res. 2012; 18 (10): 2801-2808.
23. Eferl R,. CCL2 at the crossroad of cancer metastasis. JAKSTAT 2013; 2 (2): e23816.
24. Letouzé E, Allory Y, Bollet MA, Radvanyi F, Guyon F,. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol 2010; 11 (7): R76.
25. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S,. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013 5 (169): 169ra10.
26. Nelson WG, Yegnasubramanian S,. Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discov 2013; 3 (9): 971-974.
27. Roychowdhury S, Chinnaiyan AM,. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013; 31 (15): 1866-1873.
28. Hieronymus H, Sawyers CL,. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet 2012; 44 (6): 613-614.
29. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA,. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487 (7406): 239-243.
30. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA,. Punctuated evolution of prostate cancer genomes. Cell 2013; 153 (3): 666-677.
31. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J,. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 2011; 108 (41): 17087-17092.
32. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR,. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011; 6 (11): e27970.
33. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X,. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 2013; 1-11. DOI: 10.1038/onc.2013.284
34. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM,. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 73 (2): 483-489.
35. Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP,. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2013. doi: 10.1038/onc.2013.235
36. Mitsiades N,. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 2013; 73 (15): 4599-4605.
37. Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD,. Searching for prostate cancer stem cells: Markers and methods. Stem Cell Rev 2013; 9 (5): 721-730.
38. Goldstein AS, Witte ON,. Does the microenvironment influence the cell types of origin for prostate cancer ? Genes Dev 2013; 27 (14): 1539-1544.
39. Chen S, Principessa L, Isaacs JT,. Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate 2012; 72 (13): 1478-1489.
40. Guo C, Zhang B, Garraway IP,. Isolation and characterization of human prostate stem/progenitor cells. Methods Mol Biol 2012; 879: 315-326.
41. Wilkinson SE, Furic L, Buchanan G, Larsson O, Pedersen J, Frydenberg M, Risbridger GP, Taylor RA,. Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate 2013; 73 (16): 1810-1823.
42. Brennen WN, Denmeade SR, Isaacs JT,. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer 2013; 20 (5): R269-R290. DOI: 10.1530/ERC-13-0151
43. Barron DA, Rowley DR,. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012; 19 (6): R187-R204. DOI: 10.1530/ERC-12-0085
44. Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M,. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs 2013; 22 (11): 1385-1400.
45. Graff JN, Drake CG, Beer TM,. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: A case report with implications for future research. Urology 2013; 81 (2): 381-383.
46. Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, Netto GJ, Pardoll DM, Drake CG,. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 2013; 11: 89. DOI: 10.1186/1479-5876-11-89
47. Sharma P, Wagner K, Wolchok JD, Allison JP,. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 2011; 11 (11): 805-812.
48. Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP,. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012; 72 (2): 430-439.
49. Antonarakis ES, Drake CG,. Combining immunological and androgen-directed approaches: An emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012; 24 (3): 258-265.
50. Jadvar H,. Molecular imaging of prostate cancer with PET. J Nucl Med 2013; 54 (10): 1685-1688.
51. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG,. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012; 53 (12): 1883-1891.
52. Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI,. Monitoring the clinical outcomes in advanced prostate cancer: What imaging modalities and other markers are reliable ? Semin Oncol 2013; 40 (3): 375-392.
53. Thomas MA, Nagarajan R, Huda A, Margolis D, Sarma MK, Sheng K, Reiter RE, Raman SS,. Multidimensional MR spectroscopic imaging of prostate cancer in vivo. NMR Biomed 2013; doi: 10.1002/nbm.2991
54. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM,. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19 (5): 664-678.
55. Thomas C, Lamoureux F, Crafter C, Davies BR, Beralidi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A,. Synergistic targeting of PI3K/AKT-pathway and androgen-receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2013; 12 (11): 2342-2355.
56. Beltran H, Rubin MA,. New strategies in prostate cancer: Translating genomics into the clinic. Clin Cancer Res 2013; 19 (3): 517-523.
57. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, Graeber TG, Witte ON,. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression Proc Natl Acad Sci USA 2012; 109 (5): 1643-1648.
58. Schoenborn JR, Nelson P, Fang M,. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res 2013; 19 (15): 4058-4066.
59. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS,. Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat Rev Clin Oncol 2013; 10 (10): 571-587.
60. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT,. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci USA 2013; 110 (2): E170-E179.
61. Lin D, Gout PW, Wang Y,. Lessons from in-vivo models of castration-resistant prostate cancer. Curr Opin Urol 2013; 23 (3): 214-219.
62. Michiel Sedelaar JP, Dalrymple SS, Isaacs JT,. Of mice and men-Warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 2013; 73 (12): 1316-1325.
63. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH,. Molecular classification of prostate cancer progression: Foundation for marker-driven treatment of prostate cancer. Cancer Discov 2013; 3 (8): 849-861.
64. Gallick GE, Corn PG, Zurita AJ, Lin SH,. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 2012; 4 (1): 107-119.
65. Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF Jr, Burkhart RA, McClendon AK, McCue PA, Trabulsi EJ, Lallas CD, Gomella LG, Centenera MM, Brody JR, Butler LM, Tilley WD, Knudsen KE,. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene 2013; doi: 10.1038/onc.2013.83
66. Lim AC, Attard G,. Improved therapeutic targeting of the androgen receptor: Rational drug design improves survival in castration-resistant prostate cancer. Curr Drug Targets 2013; 14 (4): 408-419.
67. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D,. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485 (7396): 55-61.
68. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S,. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 2011; 10 (5): 902-914.